Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Report 2026

Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview

• Primary Progressive Multiple Sclerosis (PPMS) Treatment market size has reached to $1.16 billion in 2025 • Expected to grow to $2.18 billion in 2030 at a compound annual growth rate (CAGR) of 13.5% • Growth Driver: The Growing Demand For Effective Treatments Is Fueling The Market Growth Due To The Rising Prevalence Of Chronic And Complex Conditions • Market Trend: Monoclonal Antibody Drug Innovations Driving Growth In The Market Due To Targeted Immune Modulation • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

Primary progressive multiple sclerosis (PPMS) treatment refers to the medical and therapeutic interventions aimed at managing and slowing the progression of PPMS, a type of multiple sclerosis characterized by a gradual worsening of neurological function from the onset of symptoms without distinct relapses or remissions. These treatments focus on modifying disease activity, alleviating symptoms, maintaining mobility, and improving quality of life. The main drug types used in the treatment of primary progressive multiple sclerosis (PPMS) include monoclonal antibodies, immunosuppressants, corticosteroids, and other drug types. Monoclonal antibodies (mAbs) are laboratory-made proteins engineered to precisely target and bind to specific antigens on diseased cells for diagnostic or therapeutic purposes. These drugs are administered through various routes, such as oral, intravenous, and other methods, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels.

What Is The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Growth Forecast?

The primary progressive multiple sclerosis (ppms) treatment market size is expected to see rapid growth in the next few years. It will grow to $2.18 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to introduction of targeted monoclonal antibodies, increasing r&d in neurodegenerative disorders, expansion of hospital and online pharmacy networks, rising regulatory approvals for novel therapeutics, growth in patient awareness and early diagnosis programs. Major trends in the forecast period include rising adoption of monoclonal antibodies for ppms, increased focus on symptom management and quality of life, growth in intravenous drug administration preference, expansion of hospital and specialty pharmacy channels, development of novel therapeutics and combination therapies.

Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Segmentation

1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types 2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels Subsegments: 1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab 2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide 3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone 4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone

What Is The Driver Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

The growing demand for effective treatments is expected to propel the growth of the primary progressive multiple sclerosis (PPMS) treatment market going forward. Effective treatments are medical interventions that reduce symptoms, improve patient outcomes, or cure a disease or condition. The growing demand for effective treatments is primarily driven by the rising prevalence of chronic and complex health conditions, which require long-term management and advanced therapeutic interventions to improve patient outcomes and quality of life. Effective treatments help slow the progression of primary progressive multiple sclerosis (PPMS) by targeting inflammation and preserving neurological function, thereby improving long-term quality of life, reducing disability accumulation, and enhancing patients’ ability to manage daily activities with greater independence and stability. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, the number of gene therapies in Phase III clinical trials reached 33 Phase III gene therapy trials in 2023, an increase of 10% compared to 2022, representing the first quarterly increase since Q3 2022. Therefore, the growing demand for effective treatments drives the growth of the primary progressive multiple sclerosis (PPMS) treatment industry.

Key Players In The Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA

Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Trends and Insights

Major companies operating in the primary progressive multiple sclerosis (PPMS) treatment market are focusing on developing innovative formulations such as monoclonal antibody drugs to enhance treatment of multiple sclerosis. A monoclonal antibody drug helps in multiple sclerosis by targeting specific immune cells or proteins that cause inflammation and damage to the nervous system, reducing disease activity and slowing the progression of symptoms. For instance, in February 2024, Roche Pharma India, an India-based pharmaceutical company, launched Ocrevus (ocrelizumab), a monoclonal antibody drug, to treat multiple sclerosis (MS) in India. Ocrevus is notable for being the first and only approved disease-modifying therapy (DMT) for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in the country. The drug works by targeting CD20-positive B cells, a type of immune cell involved in the abnormal immune response seen in MS. It is administered as a twice-yearly intravenous infusion for only two hours, offering patients a more convenient and effective treatment option.

What Are Latest Mergers And Acquisitions In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

In March 2024, Viatris Inc., a US-based healthcare company focused on providing access to medicines, partnered with Mapi Pharma Ltd. to advance the development and commercialization of GA Depot 40 mg for multiple sclerosis treatment. Through this partnership, Viatris supports the regulatory and commercial pathway for GA Depot, a long-acting injectable therapy to improve treatment adherence and address unmet medical needs in managing multiple sclerosis. Mapi Pharma Ltd. is an Israel-based pharmaceutical company specializing in depot technologies and sustained-release formulations for central nervous system disorders, including multiple sclerosis.

Regional Insights

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?

The primary progressive multiple sclerosis (PPMS) treatment market consists of sales of ocrelizumab (ocrevus), mitoxantrone, baclofen, modafinil and oxybutynin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Report 2026?

The primary progressive multiple sclerosis (ppms) treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the primary progressive multiple sclerosis (ppms) treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.